Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker approved for multiple inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis, and juvenile psoriatic arthritis, demonstrating efficacy in reducing signs and symptoms, inhibiting structural damage progression, and improving physical function across these indications.

Therapeutic Profile of Enbrel (Etanercept): Mechanism and Clinical Efficacy in Inflammatory Disorders

Enbrel (etanercept) functions as a TNF blocker, inhibiting the inflammatory cascade initiated by tumor necrosis factor. This mechanism is fundamental to its therapeutic effect across multiple inflammatory conditions, though specific pharmacodynamic details are not specified in the description.